Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
 - EconoTimes)
Active Biotech's Annual Report 2016 is now available för download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The English version will be available within short.
Lund, May 18, 2017
Tomas Leanderson
President & CEO
For further information, please contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14.30 am CET on May 18, 2017.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ed0692b0-c7c4-4c9a-9f8a-e924a3ed2a54
